A citation-based method for searching scientific literature

Junwei Shi, Christopher R Vakoc. Mol Cell 2014
Times Cited: 536







List of co-cited articles
673 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Selective inhibition of BET bromodomains.
Panagis Filippakopoulos, Jun Qi, Sarah Picaud, Yao Shen, William B Smith, Oleg Fedorov, Elizabeth M Morse, Tracey Keates, Tyler T Hickman, Ildiko Felletar,[...]. Nature 2010
42

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Jake E Delmore, Ghayas C Issa, Madeleine E Lemieux, Peter B Rahl, Junwei Shi, Hannah M Jacobs, Efstathios Kastritis, Timothy Gilpatrick, Ronald M Paranal, Jun Qi,[...]. Cell 2011
25

Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Jakob Lovén, Heather A Hoke, Charles Y Lin, Ashley Lau, David A Orlando, Christopher R Vakoc, James E Bradner, Tong Ihn Lee, Richard A Young. Cell 2013
24

Suppression of inflammation by a synthetic histone mimic.
Edwige Nicodeme, Kate L Jeffrey, Uwe Schaefer, Soren Beinke, Scott Dewell, Chun-Wa Chung, Rohit Chandwani, Ivan Marazzi, Paul Wilson, Hervé Coste,[...]. Nature 2010
20

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription.
Moon Kyoo Jang, Kazuki Mochizuki, Meisheng Zhou, Ho-Sang Jeong, John N Brady, Keiko Ozato. Mol Cell 2005
858
20

BRD4 and Cancer: going beyond transcriptional regulation.
Benedetta Donati, Eugenia Lorenzini, Alessia Ciarrocchi. Mol Cancer 2018
211
19

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Mark A Dawson, Rab K Prinjha, Antje Dittmann, George Giotopoulos, Marcus Bantscheff, Wai-In Chan, Samuel C Robson, Chun-wa Chung, Carsten Hopf, Mikhail M Savitski,[...]. Nature 2011
17

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Johannes Zuber, Junwei Shi, Eric Wang, Amy R Rappaport, Harald Herrmann, Edward A Sison, Daniel Magoon, Jun Qi, Katharina Blatt, Mark Wunderlich,[...]. Nature 2011
17

Bromodomains: a new target class for drug development.
Andrea G Cochran, Andrew R Conery, Robert J Sims. Nat Rev Drug Discov 2019
181
12

Histone recognition and large-scale structural analysis of the human bromodomain family.
Panagis Filippakopoulos, Sarah Picaud, Maria Mangos, Tracy Keates, Jean-Philippe Lambert, Dalia Barsyte-Lovejoy, Ildiko Felletar, Rudolf Volkmer, Susanne Müller, Tony Pawson,[...]. Cell 2012
955
12

BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.
Georg E Winter, Andreas Mayer, Dennis L Buckley, Michael A Erb, Justine E Roderick, Sarah Vittori, Jaime M Reyes, Julia di Iulio, Amanda Souza, Christopher J Ott,[...]. Mol Cell 2017
201
12

Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4.
Zhiyuan Yang, Jasper H N Yik, Ruichuan Chen, Nanhai He, Moon Kyoo Jang, Keiko Ozato, Qiang Zhou. Mol Cell 2005
781
12

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
Irfan A Asangani, Vijaya L Dommeti, Xiaoju Wang, Rohit Malik, Marcin Cieslik, Rendong Yang, June Escara-Wilke, Kari Wilder-Romans, Sudheer Dhanireddy, Carl Engelke,[...]. Nature 2014
622
11

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shaokun Shu, Charles Y Lin, Housheng Hansen He, Robert M Witwicki, Doris P Tabassum, Justin M Roberts, Michalina Janiszewska, Sung Jin Huh, Yi Liang, Jeremy Ryan,[...]. Nature 2016
356
11

Targeting bromodomains: epigenetic readers of lysine acetylation.
Panagis Filippakopoulos, Stefan Knapp. Nat Rev Drug Discov 2014
821
10

Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA.
Bo Huang, Xiao-Dong Yang, Ming-Ming Zhou, Keiko Ozato, Lin-Feng Chen. Mol Cell Biol 2009
398
10

BET Proteins as Targets for Anticancer Treatment.
Anastasios Stathis, Francesco Bertoni. Cancer Discov 2018
214
10

BET inhibitors: a novel epigenetic approach.
D B Doroshow, J P Eder, P M LoRusso. Ann Oncol 2017
171
9

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Emily J Faivre, Keith F McDaniel, Daniel H Albert, Srinivasa R Mantena, Joshua P Plotnik, Denise Wilcox, Lu Zhang, Mai H Bui, George S Sheppard, Le Wang,[...]. Nature 2020
143
9


Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation.
Friederike Itzen, Ann Katrin Greifenberg, Christian A Bösken, Matthias Geyer. Nucleic Acids Res 2014
129
9

Structure and ligand of a histone acetyltransferase bromodomain.
C Dhalluin, J E Carlson, L Zeng, C He, A K Aggarwal, M M Zhou. Nature 1999
9

BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain.
Ballachanda N Devaiah, Brian A Lewis, Natasha Cherman, Michael C Hewitt, Brian K Albrecht, Pamela G Robey, Keiko Ozato, Robert J Sims, Dinah S Singer. Proc Natl Acad Sci U S A 2012
243
8

STAR: ultrafast universal RNA-seq aligner.
Alexander Dobin, Carrie A Davis, Felix Schlesinger, Jorg Drenkow, Chris Zaleski, Sonali Jha, Philippe Batut, Mark Chaisson, Thomas R Gingeras. Bioinformatics 2013
8

Fast gapped-read alignment with Bowtie 2.
Ben Langmead, Steven L Salzberg. Nat Methods 2012
8

Master transcription factors and mediator establish super-enhancers at key cell identity genes.
Warren A Whyte, David A Orlando, Denes Hnisz, Brian J Abraham, Charles Y Lin, Michael H Kagey, Peter B Rahl, Tong Ihn Lee, Richard A Young. Cell 2013
8

Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting.
Shwu-Yuan Wu, A-Young Lee, Hsien-Tsung Lai, Hong Zhang, Cheng-Ming Chiang. Mol Cell 2013
203
8

The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3.
Shaila Rahman, Mathew E Sowa, Matthias Ottinger, Jennifer A Smith, Yang Shi, J Wade Harper, Peter M Howley. Mol Cell Biol 2011
338
8

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
Céline Berthon, Emmanuel Raffoux, Xavier Thomas, Norbert Vey, Carlos Gomez-Roca, Karen Yee, David Christopher Taussig, Keyvan Rezai, Christophe Roumier, Patrice Herait,[...]. Lancet Haematol 2016
274
7

Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer.
Jian Shi, Yifan Wang, Lei Zeng, Yadi Wu, Jiong Deng, Qiang Zhang, Yiwei Lin, Junlin Li, Tiebang Kang, Min Tao,[...]. Cancer Cell 2014
303
7

DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.
Georg E Winter, Dennis L Buckley, Joshiawa Paulk, Justin M Roberts, Amanda Souza, Sirano Dhe-Paganon, James E Bradner. Science 2015
786
7

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4.
Michael Zengerle, Kwok-Ho Chan, Alessio Ciulli. ACS Chem Biol 2015
457
7

Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation.
K M Sakamoto, K B Kim, A Kumagai, F Mercurio, C M Crews, R J Deshaies. Proc Natl Acad Sci U S A 2001
774
7

Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.
Pawel K Mazur, Alexander Herner, Stephano S Mello, Matthias Wirth, Simone Hausmann, Francisco J Sánchez-Rivera, Shane M Lofgren, Timo Kuschma, Stephan A Hahn, Deepak Vangala,[...]. Nat Med 2015
256
7

BET inhibitor resistance emerges from leukaemia stem cells.
Chun Yew Fong, Omer Gilan, Enid Y N Lam, Alan F Rubin, Sarah Ftouni, Dean Tyler, Kym Stanley, Devbarna Sinha, Paul Yeh, Jessica Morison,[...]. Nature 2015
345
7

Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.
Jean-Philippe Lambert, Sarah Picaud, Takao Fujisawa, Huayun Hou, Pavel Savitsky, Liis Uusküla-Reimand, Gagan D Gupta, Hala Abdouni, Zhen-Yuan Lin, Monika Tucholska,[...]. Mol Cell 2019
70
10

Targeting MYC dependence in cancer by inhibiting BET bromodomains.
Jennifer A Mertz, Andrew R Conery, Barbara M Bryant, Peter Sandy, Srividya Balasubramanian, Deanna A Mele, Louise Bergeron, Robert J Sims. Proc Natl Acad Sci U S A 2011
802
7

Model-based analysis of ChIP-Seq (MACS).
Yong Zhang, Tao Liu, Clifford A Meyer, Jérôme Eeckhoute, David S Johnson, Bradley E Bernstein, Chad Nusbaum, Richard M Myers, Myles Brown, Wei Li,[...]. Genome Biol 2008
7

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.
Michael I Love, Wolfgang Huber, Simon Anders. Genome Biol 2014
7

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
Philipp Rathert, Mareike Roth, Tobias Neumann, Felix Muerdter, Jae-Seok Roe, Matthias Muhar, Sumit Deswal, Sabine Cerny-Reiterer, Barbara Peter, Julian Jude,[...]. Nature 2015
327
7

Distinct Roles of Brd2 and Brd4 in Potentiating the Transcriptional Program for Th17 Cell Differentiation.
Ka Lung Cheung, Fan Zhang, Anbalagan Jaganathan, Rajal Sharma, Qiang Zhang, Tsuyoshi Konuma, Tong Shen, June-Yong Lee, Chunyan Ren, Chih-Hung Chen,[...]. Mol Cell 2017
73
9

Coactivator condensation at super-enhancers links phase separation and gene control.
Benjamin R Sabari, Alessandra Dall'Agnese, Ann Boija, Isaac A Klein, Eliot L Coffey, Krishna Shrinivas, Brian J Abraham, Nancy M Hannett, Alicia V Zamudio, John C Manteiga,[...]. Science 2018
881
7

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
Ali Alqahtani, Khalil Choucair, Mushtaq Ashraf, Danae M Hammouda, Abduraham Alloghbi, Talal Khan, Neil Senzer, John Nemunaitis. Future Sci OA 2019
145
7

BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones.
Tomohiko Kanno, Yuka Kanno, Gary LeRoy, Eric Campos, Hong-Wei Sun, Stephen R Brooks, Golnaz Vahedi, Tom D Heightman, Benjamin A Garcia, Danny Reinberg,[...]. Nat Struct Mol Biol 2014
181
7

BET domain co-regulators in obesity, inflammation and cancer.
Anna C Belkina, Gerald V Denis. Nat Rev Cancer 2012
467
7

BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.
Xiangyi Li, GuemHee Baek, Susmita G Ramanand, Adam Sharp, Yunpeng Gao, Wei Yuan, Jon Welti, Daniel N Rodrigues, David Dolling, Ines Figueiredo,[...]. Cell Rep 2018
57
10

Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
Lu Yang, Youyou Zhang, Weiwei Shan, Zhongyi Hu, Jiao Yuan, Jingjiang Pi, Yueying Wang, Lingling Fan, Zhaoqing Tang, Chunsheng Li,[...]. Sci Transl Med 2017
125
6

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
6

Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer.
Shipeng He, Guoqiang Dong, Yu Li, Shanchao Wu, Wei Wang, Chunquan Sheng. Angew Chem Int Ed Engl 2020
45
13

Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
Tingting Liu, Yichao Wan, Yuliang Xiao, Chengcai Xia, Guiyun Duan. J Med Chem 2020
39
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.